Novartis Piqray® – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in HR+/HER2- advanced breast cancer patients with PIK3CA mutation, compared to fulvestrant alone. Approximately 30-40% of those with HR+/HER2- subtype have a PIK3CA mutation, which is associated with a poor prognosis. In Singapore, the […]
By Chauncey K. Robinson The Biden administration has introduced a sweeping new immigration bill that stands in stark contrast to Donald Trump’s four years of attacks on undocumented workers and their families. The new bill is being seen by many as a bold step in a better direction, but some immigrant rights activists are […]